Xiuning Le, MD, PhD | Authors

Xiuning Le, MD, PhD, Discusses Who May Benefit Most From Tepotinib in Advanced NSCLC

July 04, 2022

Xiuning Le, MD, PhD, spoke about which patients with advanced non–small cell lung cancer with high MET-amplification could benefit most from tepotinib based on molecular markers.

Xiuning Le, MD, PhD, Discusses Key Efficacy Data With Tepotinib in Advanced NSCLC

June 21, 2022

Xiuning Le, MD, PhD, spoke about the use of ctDNA biomarkers and why research should continue for those with advanced non–small cell lung cancer with high MET-amplification being treated with tepotinib.

Xiuning Le, MD, PhD, on the Rationale for Assessing Tepotinib in Advanced NSCLC

June 20, 2022

Xiuning Le, MD, PhD, spoke about unmet needs in patients with advanced non–small cell lung cancer with high MET-amplifications and why tepotinib may be a good treatment option.